Billing Part B vs. Part D for Anti-emetic Drugs
Not sure if you should bill Part B or Part D for a drug regimen of aprepitant when used to alleviate chemotherapy induced nausea-vomiting (CINV)? You’re not alone. To answer an influx of questions pertaining to anti-emetic drugs, the Centers for Medicare & Medicaid Services (CMS) recently issued MLN Matters SE0910.
In MM SE0910, you will find guidance for billing aprepitant when used as a complete replacement for intravenous therapy or as a completion of a 48-hour regimen where IV aprepitant is given the day of chemotherapy and the oral medication is given days 2-3 of therapy.
- Message From Your Region 6 Representatives | Pam Tienter and Jean Pryor - January 16, 2020
- Message From Your Region 3 Representatives | Astara Crews and Dianne Estes - January 16, 2020
- Message From Your Region 7 Representatives | Robert Kiesecker and Pam Brooks - January 16, 2020